Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study

• Status: Unknown status
• Trial end date: 2018-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Neovascular glaucoma is a potentially blinding condition characterized by the growth of newvessels at the anterior part of the eye. This growth is driven by the overexpression of a protein called Vascular Endothelial Growth Factor (VEGF). That happens in diseases such as diabetic retinopathy or venous retinal occlusion, and lead to a fast increase in intraocular pressure (IOP). Traditional treatment include laser photocoagulation of the retina in order to decrease VEGF formation. The investigators postulate that the use of anti-VEGF intravitreal injections may accelerate recovery and decrease the need of surgery in cases of neovascular glaucoma.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: LEANDRO CABRAL ZACHARIAS
• Collaborator: Novartis
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• IOP greater than 24 mmHg

• Iris or anterior chamber neovascularization

• At least 120 degrees of opened anterior chamber angle

Exclusion Criteria:

• Visual acuity worse than counting fingers in the fellow eye

• No light perception in the treated eye

• Any ocular infectious disease

• Use of systemic steroids

• Lack of media transparency precluding laser photocoagulation

• Thromboembolic disease

• Known hypersensitivity to ranibizumab

• Female participants at childbearing age not using oral contraceptives

• Use of intravitreal anti-VEGF over the last 30 days.